BTG, a medical innovations company, has already received $5.8m as a result of Zebra exercising options to buy and from the sale of other patents.
The firm will receive an additional $1.4m in relation to the sale of these and other RFID patents on satisfaction of certain conditions.
Louise Makin, chief executive officer, said: “We are pleased with the sale of our remaining RFID patents to Zebra.
“This divestment is in line with our strategy to exit and realise value from our non-core technology areas whilst expanding and developing our pipeline of medical products.”
BTG has previously also earned $5m from the sale of its WebNav online tracking patents in the first half of the current financial year.
© Crimson Business Ltd 2006
